Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 139 JPY -2.79% Market Closed
Market Cap: 281.2B JPY
Have any thoughts about
Sawai Group Holdings Co Ltd?
Write Note

Sawai Group Holdings Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sawai Group Holdings Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Sawai Group Holdings Co Ltd
TSE:4887
Accounts Receivables
ÂĄ57.2B
CAGR 3-Years
-7%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Accounts Receivables
ÂĄ700.5B
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Daiichi Sankyo Co Ltd
TSE:4568
Accounts Receivables
ÂĄ531.8B
CAGR 3-Years
24%
CAGR 5-Years
9%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Accounts Receivables
ÂĄ470.4B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Accounts Receivables
ÂĄ239.7B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
6%
Astellas Pharma Inc
TSE:4503
Accounts Receivables
ÂĄ558.3B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
5%
No Stocks Found

Sawai Group Holdings Co Ltd
Glance View

Market Cap
265.2B JPY
Industry
Pharmaceuticals

Sawai Group Holdings Co., Ltd. stands as a prominent figure in the pharmaceutical landscape of Japan and beyond, rooted in a steadfast commitment to produce affordable generic medicines. Originating from humble beginnings in 1929, Sawai has evolved into a formidable player in the industry, underpinned by a strategy that blends innovation with an intricate understanding of healthcare needs. Known for its sharp focus on generic pharmaceutical products, the company has carved a niche by prioritizing the development and manufacture of high-quality, cost-efficient medications. This strategic orientation not only aligns with global healthcare trends but also meets the burgeoning demands of an aging population, both domestically and internationally. Central to Sawai's business model is their vertically integrated operation, covering everything from research and development to manufacturing and distribution. This comprehensive approach allows Sawai to maintain strict control over product quality while maximizing operational efficiency. Revenue flows from its diverse product portfolio, which includes a vast array of therapeutic areas such as cardiovascular, digestive, and central nervous system drugs. Moreover, Sawai's expansion into international markets, particularly in the United States through its subsidiary Upsher-Smith Laboratories, broadens its revenue base. By leveraging strategic acquisitions and partnerships, the company continues to fortify its presence on the global stage, all while steadfastly delivering on its promise of making healthcare accessible and affordable.

Intrinsic Value
2 890.58 JPY
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Sawai Group Holdings Co Ltd's Accounts Receivables?
Accounts Receivables
57.2B JPY

Based on the financial report for Mar 31, 2024, Sawai Group Holdings Co Ltd's Accounts Receivables amounts to 57.2B JPY.

What is Sawai Group Holdings Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
1%

Over the last year, the Accounts Receivables growth was -15%. The average annual Accounts Receivables growth rates for Sawai Group Holdings Co Ltd have been -7% over the past three years , 1% over the past five years .

Back to Top